Lungometer

If your patient is on ICS/LABA therapy; check exacerbations occurrence: 1,2

Trelegy Ellipta
Exacerbations
EXACERBATIONS

Do they experience ≥2/year frequent exacerbation requiring OCS, or ≥1/year serious exacerbations requiring hospitalization?

If your patient is on ICS/LABA therapy, check whether any of the following occurred during the past 4 weeks: 1,2

Activity limitation
ACTIVITY LIMITATION

Has Asthma limited patient daily activity?

Shortness of breath
SHORTNESS OF BREATH

Have they experienced episodes of shortness of breath?

Night symptoms
NIGHT SYMPTOMS

Have Asthma Symptoms disturbed their sleep or caused early awakening?

Rescue inhaler use
RESCUE INHALER USE

Have they frequently relied on a rescue inhaler or nebulizer?

GSK
         Trelegy Contraindications:3   Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required or severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any of the excipients.  •  References:   1. Global Initiative for Asthma (GINA). Difficult-to-treat and severe asthma in adolescent and adult patients: diagnosis and management. 2024. Available from: https://ginasthma.org/wp-content/uploads/11/2024/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf  •    2. Saudi Initiative for Asthma (SINA). 2024 Update: Guidelines for Diagnosis and Management of Asthma in Adults and Children. Saudi Thoracic Society. Available at: https://saudithoracicsociety.org/wp-content/uploads/11/2023/Saudi_Initiative_for_Asthma_2024.pdf  •    3. TRELEGY Ellipta Product Information  •    4. Illustration adapted from Nata SC, Launico MV. Anatomy, Airway. [Updated 2025 Sep 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. [Figure, Respiratory System]. Available from: https://www.ncbi.nlm.nih.gov/sites/books/NBK459258/figure/article-17308.image.f1/  •    Disclaimer   GSK does not recommend, endorse, or accept liability for sites controlled by a third party.    For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia. Telephone: +96612 653 6666 or via gcc.medinfo@gsk.com    To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com    To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via KSA.ProductQualityComplaint@gsk.com    © 2026 GlaxoSmithKline group of companies or its licensor. All rights reserved.    GlaxoSmithKline Limited, Registered in Saudi Arabia. P.O. Box 55850, Jeddah 21544, Saudi Arabia.    Trelegy PI https://assets.gskinternet.com/pharma/GSKpro/Saudi/Trelegy/trelegy_ellipta_asthma_pi_saudi.pdf PM-SA-FVU-WCNT-260010 - Date of preparation: May 2026